Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia
- 15 September 2004
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 94 (6) , 795-797
- https://doi.org/10.1016/j.amjcard.2004.06.008
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Annexin 2–caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transportProceedings of the National Academy of Sciences, 2004
- Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol AbsorptionScience, 2004
- Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatmentEuropean Journal of Clinical Investigation, 2003
- Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitorClinical Therapeutics, 2003
- Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemiaJournal of the American College of Cardiology, 2002
- Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemiaThe American Journal of Cardiology, 2002
- Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in HumansCirculation, 2002
- Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled TrialMayo Clinic Proceedings, 2001
- Colesevelam Hydrochloride: A Novel Bile Acid-Binding ResinAnnals of Pharmacotherapy, 2001
- Colesevelam Hydrochloride (Cholestagel)Archives of internal medicine (1960), 1999